Samith T. Kochuparambil

Author

Also Known As

Ronald Harris, S T Kochuparambil, S. T. Kochuparambil, S. Thomas Kochuparambil, S.T. Kochuparambil, Samith Kochuparambil, Samith T Kochuparambil, Samith T. Kochuparambil, Samith Thomas Kochuparambil

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Rush University Medical Center The University of Texas MD Anderson Cancer Center Augusta University Health West Virginia University University of Oklahoma Health Sciences Center

About

Samith T. Kochuparambil is an author at Rush University Medical Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	127
2	Health Sciences	2	2	56
3	Immunology	1	1	49
4	Pharmacology	1	1	22
5	Surgical Oncology	1	1	29

Samith T. Kochuparambil

Publications

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Phase 1/2a, open‐label, multicenter study of <scp>RM</scp>‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma David M. Cognetti, Jennifer M. Johnson, Joseph Curry, Head & Neck	2021	157
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma Raffit Hassan, Anish Thomas, John Nemunaitis, JAMA Oncology	2019	149
Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression Samith T. Kochuparambil, Belal Al‐Husein, Anna Goc, Journal of Pharmacology and Experimental Therapeutics	2010	133
Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis Anna Goc, Samith T. Kochuparambil, Belal Al‐Husein, BMC Cancer	2012	79
Intermediate-Dose versus Low-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Treated with Novel Induction Therapies Mehdi Hamadani, Samith T. Kochuparambil, Salman Osman, Biology of Blood and Marrow Transplantation	2012	71
Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies Farrukh T. Awan, Samith T. Kochuparambil, Debbie Falconer, Bone Marrow Transplantation Hematological MalignancyOncologyPbsc MobilizationMetronomic TherapyImmunology	2013	49
Evaluation of Circulating Tumor DNA for Methylated <i>BCAT1</i> and <i>IKZF1</i> to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC) Benjamin Musher, Joshua Melson, Gianni Amato, Cancer Epidemiology Biomarkers & Prevention	2020	32
Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). David M. Cognetti, Jennifer M. Johnson, Joseph Curry, Journal of Clinical Oncology Surgical OncologyOncologic ImagingDermatologyOncologyMetronomic Therapy	2019	29
RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial. Ann M. Gillenwater, David M. Cognetti, Jennifer M. Johnson, Journal of Clinical Oncology Neck CancerOncologic ImagingRecurrent HnsccImmunotherapyOncology	2018	27

Page 1